Hepalife Technologies Inc.
60 State St
Ste 700
Boston
MA
02109
United States
(800) 518-4879
Product(s):
Develops a bioartificial liver device, HepaLife, to treat liver failure using a patented PICM-19 liver stem cell line; and testing platforms to improve the evaluation of drug toxicity and side effects
Ownership:
Public
Exchange:
OTC BB
symbol:
HPLF.OB
Yahoo Quotes:
Chairman:
Frank Menzler
President:
Frank Menzler
CEO:
Frank Menzler Management:
Donna A. Lopolito, CFO
Shawn P. Cain, director-product development
Richard E. Kruger, director-regulatory affairs
Hepalife Technologies Inc.
Permalink
RECENT BLOG POSTS
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
- Physician blogger insights on social media
